Joel N. Buxbaum

12.7k total citations · 4 hit papers
153 papers, 8.3k citations indexed

About

Joel N. Buxbaum is a scholar working on Molecular Biology, Physiology and Cell Biology. According to data from OpenAlex, Joel N. Buxbaum has authored 153 papers receiving a total of 8.3k indexed citations (citations by other indexed papers that have themselves been cited), including 119 papers in Molecular Biology, 46 papers in Physiology and 37 papers in Cell Biology. Recurrent topics in Joel N. Buxbaum's work include Amyloidosis: Diagnosis, Treatment, Outcomes (85 papers), Alzheimer's disease research and treatments (39 papers) and Cellular transport and secretion (26 papers). Joel N. Buxbaum is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (85 papers), Alzheimer's disease research and treatments (39 papers) and Cellular transport and secretion (26 papers). Joel N. Buxbaum collaborates with scholars based in United States, Italy and Sweden. Joel N. Buxbaum's co-authors include Maria João Saraiva, Natàlia Reixach, Giampaolo Merlini, Per Westermark, Merrill D. Benson, Jean D. Sipe, Jeffery W. Kelly, Daniel R. Jacobson, Shu-ichi Ikeda and Gloria Gallo and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Joel N. Buxbaum

153 papers receiving 8.0k citations

Hit Papers

Amyloid fibril proteins and amyloidosis: chemical identif... 2016 2026 2019 2022 2016 2018 2020 2022 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines
    2016 438 citations Joel N. Buxbaum, Maria João Saraiva et al. Amyloid profile →
  2. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee
    2018 396 citations Joel N. Buxbaum, Maria João Saraiva et al. Amyloid profile →
  3. Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee
    2020 268 citations Joel N. Buxbaum, Maria João Saraiva et al. Amyloid profile →
  4. Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee
    2022 184 citations Joel N. Buxbaum, Maria João Saraiva et al. Amyloid profile →

Peers

Joel N. Buxbaum
Merrill D. Benson United States
Yoshiki Sekijima Japan
Edward Y. Skolnik United States
Jørgen Gliemann Denmark
Atsushi Enomoto Japan
Hirotoshi Tanaka Japan
Kenneth E. Bernstein United States
Andrew P. Levy Israel
Armen H. Tashjian United States
Ellen Van Obberghen‐Schilling France
Merrill D. Benson United States
Joel N. Buxbaum
Citations per year, relative to Joel N. Buxbaum Joel N. Buxbaum (= 1×) peers Merrill D. Benson

Countries citing papers authored by Joel N. Buxbaum

Since Specialization
Citations

This map shows the geographic impact of Joel N. Buxbaum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel N. Buxbaum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel N. Buxbaum more than expected).

Fields of papers citing papers by Joel N. Buxbaum

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel N. Buxbaum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel N. Buxbaum. The network helps show where Joel N. Buxbaum may publish in the future.

Co-authorship network of co-authors of Joel N. Buxbaum

This figure shows the co-authorship network connecting the top 25 collaborators of Joel N. Buxbaum. A scholar is included among the top collaborators of Joel N. Buxbaum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joel N. Buxbaum. Joel N. Buxbaum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cheng, Shi‐Bin, Zheping Huang, Sayani Banerjee, et al.. (2022). Evidence From Human Placenta, Endoplasmic Reticulum–Stressed Trophoblasts, and Transgenic Mice Links Transthyretin Proteinopathy to Preeclampsia. Hypertension. 79(8). 1738–1754. 16 indexed citations
2.
3.
Satapathy, Sandeep, Daniel R. Whiten, Megan A. Kelly, et al.. (2021). Neuroserpin and transthyretin are extracellular chaperones that preferentially inhibit amyloid formation. Science Advances. 7(50). eabf7606–eabf7606. 11 indexed citations
4.
5.
Buxbaum, Joel N. & Reinhold P. Linke. (2012). A Molecular History of the Amyloidoses. Journal of Molecular Biology. 421(2-3). 142–159. 118 indexed citations
6.
Li, Xinyi & Joel N. Buxbaum. (2011). Transthyretin and the brain re-visited: Is neuronal synthesis of transthyretin protective in Alzheimer's disease?. Molecular Neurodegeneration. 6(1). 79–79. 84 indexed citations
7.
8.
Li, Xinyi, Eliezer Masliah, Natàlia Reixach, & Joel N. Buxbaum. (2011). Neuronal Production of Transthyretin in Human and Murine Alzheimer's Disease: Is It Protective?. Journal of Neuroscience. 31(35). 12483–12490. 113 indexed citations
9.
Soares, Miguel Luz, Teresa Coelho, Alda Sousa, et al.. (2005). Susceptibility and modifier genes in Portuguese transthyretin V30M amyloid polyneuropathy: complexity in a single-gene disease. Human Molecular Genetics. 14(4). 543–553. 94 indexed citations
10.
Tagoe, Clément E., Daniel R. Jacobson, Gloria Gallo, & Joel N. Buxbaum. (2003). Mice transgenic for human TTR have the same frequency of renal TTR deposition whether maintained in conventional or specific pathogen free environments. Amyloid. 10(4). 262–266. 6 indexed citations
11.
Vidal, Rubén, Jorge Ghiso, Asok Kumar, et al.. (2001). Amyloid and Nonfibrillar Deposits in Mice Transgenic for Wild-Type Human Transthyretin: A Possible Model for Senile Systemic Amyloidosis. Laboratory Investigation. 81(3). 385–396. 79 indexed citations
12.
Jacobson, Daniel R., et al.. (1997). Variant-Sequence Transthyretin (Isoleucine 122) in Late-Onset Cardiac Amyloidosis in Black Americans. New England Journal of Medicine. 336(7). 466–473. 407 indexed citations
13.
Alves, Isabel L., et al.. (1996). Transthyretin Ser6 as a neutral polymorphism in familial amyloidotic polyneuropathy. Amyloid. 3(4). 242–244. 7 indexed citations
14.
Garte, Seymour, Frances Crofts, Paolo Toniolo, et al.. (1996). Distribution of Composite CYP1A1 Genotypes in Africans, African-Americans and Caucasians. Human Heredity. 46(3). 121–127. 44 indexed citations
15.
Davis, Mark M. & Joel N. Buxbaum. (1995). T-cell receptor use in human autoimmune diseases. New York Academy of Sciences eBooks. 6 indexed citations
16.
Shiffman, Saul, Barrie R. Cassileth, Joel N. Buxbaum, et al.. (1991). Needs and recommendations for behavior research in the prevention and early detection of cancer. Cancer. 67(S3). 800–804. 7 indexed citations
17.
Goñi, Fernando, Joseph V. Chuba, Joel N. Buxbaum, & B Frangione. (1988). A double monoclonal IgG1 kappa and IgG2 kappa in a single myeloma patient. Variation in clonal products and therapeutic responses.. The Journal of Immunology. 140(2). 551–557. 9 indexed citations
18.
Jacobson, D R, et al.. (1987). Identification of new restriction fragment length polymorphisms associated with familial amyloidotic polyneuropathy. Clinical research. 35(3). 594. 2 indexed citations
19.
Buxbaum, Joel N. & Matthew D. Scharff. (1973). THE SYNTHESIS, ASSEMBLY, AND SECRETION OF GAMMA GLOBULIN BY MOUSE MYELOMA CELLS. The Journal of Experimental Medicine. 138(1). 278–288. 21 indexed citations
20.
Buxbaum, Joel N., et al.. (1971). SYNTHESIS AND ASSEMBLY OF IMMUNOGLOBULINS BY MALIGNANT HUMAN PLASMACYTES AND LYMPHOCYTES. The Journal of Experimental Medicine. 133(5). 1118–1130. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Merrill D. Benson Breakdown of academic impact, for papers by Yoshiki Sekijima Breakdown of academic impact, for papers by Edward Y. Skolnik Breakdown of academic impact, for papers by Jørgen Gliemann Breakdown of academic impact, for papers by Atsushi Enomoto Breakdown of academic impact, for papers by Hirotoshi Tanaka Breakdown of academic impact, for papers by Kenneth E. Bernstein Breakdown of academic impact, for papers by Andrew P. Levy Breakdown of academic impact, for papers by Armen H. Tashjian Breakdown of academic impact, for papers by Ellen Van Obberghen‐Schilling
Rankless by CCL
2026